Contrasting of Coherus BioSciences Inc. (CHRS) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)

This is a contrast between Coherus BioSciences Inc. (NASDAQ:CHRS) and Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. 18 11.69 N/A -2.66 0.00
Eloxx Pharmaceuticals Inc. 10 0.00 N/A -1.47 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Coherus BioSciences Inc. and Eloxx Pharmaceuticals Inc.


Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% 0% -120.3%
Eloxx Pharmaceuticals Inc. 0.00% -107.1% -88.5%

Volatility & Risk

Coherus BioSciences Inc. is 205.00% more volatile than Standard & Poor’s 500 due to its 3.05 beta. From a competition point of view, Eloxx Pharmaceuticals Inc. has a 1.71 beta which is 71.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio of Coherus BioSciences Inc. is 3.8 while its Quick Ratio stands at 3.8. The Current Ratio of rival Eloxx Pharmaceuticals Inc. is 6.6 and its Quick Ratio is has 6.6. Eloxx Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Coherus BioSciences Inc.

Analyst Recommendations

In next table is given Coherus BioSciences Inc. and Eloxx Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 3 3.00
Eloxx Pharmaceuticals Inc. 0 0 0 0.00

$33.67 is Coherus BioSciences Inc.’s consensus price target while its potential upside is 66.68%. Competitively the consensus price target of Eloxx Pharmaceuticals Inc. is $20, which is potential 213.48% upside. Based on the data given earlier, Eloxx Pharmaceuticals Inc. is looking more favorable than Coherus BioSciences Inc., analysts view.

Institutional and Insider Ownership

Roughly 97.45% of Coherus BioSciences Inc. shares are owned by institutional investors while 50.1% of Eloxx Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 0.3% of Coherus BioSciences Inc.’s shares. Competitively, Eloxx Pharmaceuticals Inc. has 0.4% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. -5.51% -25.31% 5.45% 28.69% -6.56% 85.86%
Eloxx Pharmaceuticals Inc. -0.12% -17.66% -28.55% -29.23% -46.1% -32.06%

For the past year Coherus BioSciences Inc. has 85.86% stronger performance while Eloxx Pharmaceuticals Inc. has -32.06% weaker performance.


Coherus BioSciences Inc. beats Eloxx Pharmaceuticals Inc. on 5 of the 9 factors.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.